Vergelijking

Lanreotid vs. Selank

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

108736-35-2

129954-34-3

Molecuulmassa

1096.34 g/mol

751.85 g/mol

Halfwaardetijd

geen gegevens

0.3 h

Sequentie

geen gegevens

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Werkingsmechanisme

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Lanreotid	Selank
Duitsland	Op recept	Niet goedgekeurd
RU	—	Op recept
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Lanreotid

Volledige vermelding →

Selank

Volledige vermelding →

Frequently asked questions

What is the difference between Lanreotid and Selank?: Lanreotid is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lanreotid or Selank?: The highest available evidence level is "Humane RCT" for Lanreotid and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lanreotid and Selank in Germany and the United States?: Duitsland: Lanreotid — Op recept, Selank — Niet goedgekeurd. Verenigde Staten: Lanreotid — Op recept, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Lanreotid

Selank

Duitsland

Op recept

Niet goedgekeurd

—

Op recept

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Lanreotid and Selank?

Lanreotid is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lanreotid or Selank?

The highest available evidence level is "Humane RCT" for Lanreotid and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lanreotid and Selank in Germany and the United States?

Duitsland: Lanreotid — Op recept, Selank — Niet goedgekeurd. Verenigde Staten: Lanreotid — Op recept, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.